ASX Announcement: Atomo and NG Biotech expand COVID-19 partnership:
Atomo secures exclusive rights for Australia, New Zealand and South East Asia¹ SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics Limi...
04 June, 2020
Atomo’s innovative rapid diagnostic test (RDT) platforms simplify procedures, mitigate common user errors, and enhance test performance. Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic companies wanting to enhance their RDT product offerings.
Unmatched Usability
User-centred design for professional use & self-test applications.
Proven Performance
Award-winning device platforms that are proven to mitigate user errors.
Efficient Development
Validated processes to accelerate custom device development.
Integrated RDT platforms
Award-winning AtomoRapid™ RDT platforms remove the need for multiple test components by integrating features into a single device. With assorted functionality, Atomo platforms greatly simplify test procedures.
Self-testing made simpler
With a built-in safety lancet, unique blood collection feature, single action blood and buffer delivery system, and interlocked user steps, the AtomoRapid™ Elion self-test platform provides unprecedented usability and performance.
Custom device development
Devices are customisable to suit your requirements and modified to match the specifics of your test strip. From manufacturing process validation to post launch marketing, benefit from Atomo’s dedicated support every step of the way.
Atomo HIV Self Test
The Atomo HIV Self Test is now available in Australia directly from Atomo Diagnostics, and is the first and only HIV self-test to have been approved by the Australian Therapeutic Goods Administration (TGA).
Partner with Atomo for an efficient, low-risk pathway from product development to commercialisation of your best-in-class rapid diagnostic test.
Get in touch >
Atomo News
-
-
MEDIA RELEASE: Atomo Diagnostics to list on ASX after successful IPO and virtual bell ringing ceremony
SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares ...
16 April, 2020
Good piece in @BiotechDispatch on our agreement with DIVOC Labs to sell our AtomoRapid™ COVID-19 rapid antibody test in India. Read article here: https://bit.ly/32Z6rLl $AT1
Our MD, John Kelly is a panellist on the IPO Spotlight panel session at the Smallcap Virtual Showcase on Wed, 16 Sept @1pm. Registration for the session is FREE and you can register here: https://bit.ly/3hqYiDG
“We have developed a platform that supports a broad range of rapid blood based tests. We are working hard to expand the applications commercialised on our platforms”– MD, John Kelly speaks to @proactive_au at the ASX Small and Mid-Cap Conference: https://bit.ly/33m8BUi